The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 19, 2022

Filed:

Apr. 27, 2020
Applicant:

The University of Chicago, Chicago, IL (US);

Inventors:

Wenbin Lin, Chicago, IL (US);

Christina Chan, Chicago, IL (US);

Wenbo Han, Chicago, IL (US);

Assignee:

The University of Chicago, Chicago, IL (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/343 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/343 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61P 35/00 (2018.01); A61P 37/00 (2018.01); A61N 5/10 (2013.01);
Abstract

Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.


Find Patent Forward Citations

Loading…